TriSalus Life Sciences Inc
For the period ended Dec 31, 2023. Filed Apr 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 11, 2024
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
December 31, 2023 and 2022
(in thousands, except share and per share data)
| 2023 | 2022 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $11,777 | $9,414 |
| Accounts receivable | 3,554 | 1,557 |
| Inventory, net | 2,545 | 1,471 |
| Prepaid expenses | 2,986 | 4,772 |
| Total current assets | 20,862 | 17,214 |
| Property and equipment, net | 2,091 | 2,231 |
| Right-of-use assets | 1,179 | 1,381 |
| Intangible assets, net | 1,127 | 802 |
| Other assets | 466 | 367 |
| Total assets | $25,725 | $21,995 |
| Liabilities, Convertible Preferred Stock and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Trade payables | $3,391 | $4,947 |
| Accrued liabilities | 10,556 | 6,377 |
| Series B-2 tranche liabilities | — | 4,702 |
| Series B-3 warrant liabilities | — | 15,819 |
| Short-term lease liabilities | 351 | 370 |
| Other current liabilities | 389 | 142 |
| Total current liabilities | 14,687 | 32,357 |
| Long-term lease liabilities | 1,244 | 1,593 |
| Contingent earnout liability | 18,632 | — |
| Warrant liabilities and other long-term liabilities | 17,100 | 369 |
| Total liabilities | 51,663 | 34,319 |
| Convertible Preferred Stock | — | 164,006 |
| Stockholders’ deficit: | ||
| Preferred Stock, Convertible preferred stock, Series A, $0.0001 par value per share, $10.00 liquidation value per share. Authorized 10,000,000 and 0 shares at December 31, 2023 and 2022, respectively; issued and outstanding, 4,015,002 and 0 shares at December 31, 2023 and 2022, respectively | — | — |
| Common stock, $0.0001 par value per share. Authorized 400,000,000 and 30,898,162 shares at December 31, 2023 and 2022, respectively; issued and outstanding 26,413,213 shares and 347,926 shares at December 31, 2023 and 2022, respectively | 2 | — |
| Additional paid-in capital | 222,437 | 10,028 |
| Accumulated deficit | (248,377) | (186,358) |
| Total stockholders’ deficit | (25,938) | (176,330) |
| Total liabilities, convertible preferred stock and stockholders’ deficit | $25,725 | $21,995 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.